Scientific letter N°1

April 18, 2008 marks the new beginning of the Atlanchim company. After more than 4 years of quality services, the company Atlanchim changes direction and becomes at the same time ATLANCHIM PHARMA. This change of direction was made under the impetus of the company ATLANTIC BONE SCREEN.
The respective expertise of the two companies both in the custom synthesis of chemical molecules (ATLANCHIM PHARMA) and in the evaluation of the biological activity of molecules (ATLANTIC BONE SCREEN), show the complementarity of interests and skills are the basis the merger of the two structures.
Each of the two structures retains its own activity, but the merger of ATLANCHIM PHARMA and ATLANTIC BONE SCREEN will result in the strengthening of their activities in medicinal chemistry.
The scientific directors (Pr. Jacques LEBRETON and Dr. André GUINGANT) as well as the 4 project managers of the initial team retain their functions within ATLANCHIM PHARMA. Their presence in the new company is a guarantee of continuity and expertise with regard to the quality of present and future activities.
Also our wish is to continue to offer the services initially provided and a professional approach to projects, but also to develop and expand the range of services for our customers and partners and in particular the establishment of flexible research contracts with staff dedicated.
The complementarity of skills and the synergy of interest of the companies ATLANTIC BONE SCREEN and ATLANCHIM PHARMA will allow you to increase and accelerate the development of your compounds.

Ronan LE BOT